Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
- Study Title
- Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel
- Teva Identifier
- NEUGR-002
- ClinicalTrials.gov Identifier
- NCT00837265
- Study Status
- Completed
- Trial Condition(s)
- Chemotherapy-induced Neutropenia
- Interventions
- Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- 08/01/2008 - 07/01/2010
- Phase
- Phase 2/3